{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:11:35Z","timestamp":1789269095827,"version":"build-2803163510"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Granulocyte colony-stimulating factors (G-CSFs) include long-acting ones and short-acting ones. They have been mainly applied in Chinese clinical practice for years to prevent neutropenia. However, which type of G-CSF is more superior has not been conclusively determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic literature search was conducted using the PubMed, Embase, Cochrane Library, clinical trials.gov, China National Knowledge Infrastructure, and WAN FANG databases for related studies published till August 2021. Revman 5.3 software was used to assess the effectiveness and safety of these 2 types of G-CSFs in patients undergoing chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Ten studies involving 1916 patients were included in our meta-analysis to compare the effectiveness and safety of long-acting G-CSFs and short-acting G-CSFs. We found that the incidence of febrile neutropenia (relative risk [RR] 0.82; 95% confidence interval [CI] 0.57\u20131.17), the recovery time of the absolute neutrophil count (mean difference \u20130.23; 95% CI \u20130.49 to 0.03), and the fatigue rate (RR 0.82; 95% CI 0.62\u20131.07) were similar between the long- and the short-acting G-CSFs. However, the long-acting G-CSFs significantly decreased the incidence (RR 0.86; 95% CI 0.76\u20130.96) and shortened the duration (mean difference \u20130.19; 95% CI \u20130.38 to 0.00) of severe (grade \u22653) neutropenia, and decreased the rate of bone and\/or muscle pain (RR 0.75; 95% CI 0.58\u20130.98).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Primary prophylaxis with long-acting G-CSFs was more effective and safer than primary prophylaxis with short-acting G-CSFs in Chinese adults undergoing chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028218","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:31:20Z","timestamp":1640287880000},"page":"e28218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China"],"prefix":"10.1097","volume":"100","author":[{"given":"Genzhu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Capital Medical University Electric Teaching Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghe","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Shijiazhuang Pharmaceutical Group, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Capital Medical University Electric Teaching Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Capital Medical University Electric Teaching Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikun","family":"Xun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Capital Medical University Electric Teaching Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Capital Medical University Electric Teaching Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0382-3136","authenticated-orcid":false,"given":"Zhongdong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Capital Medical University Electric Teaching Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharmacol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jca.21550","article-title":"Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis","volume":"32","author":"Kuan","year":"2017","journal-title":"J Clin Apher"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/TCRM.S48387","article-title":"Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study","volume":"9","author":"Rossi","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","article-title":"Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis","volume":"11","author":"Cooper","year":"2011","journal-title":"BMC Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","article-title":"Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN study","volume":"18","author":"Almenar","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1995-7645(13)60163-7","article-title":"Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage","volume":"6","author":"Yan","year":"2013","journal-title":"Asian Pac J Trop Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001813-200304000-00002","article-title":"Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients","volume":"14","author":"Molineux","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40261-019-00836-y","article-title":"Mecapegfilgrastim in chemotherapy-induced neutropenia: a profile of its use in China","volume":"39","author":"Al-Salama","year":"2019","journal-title":"Clin Drug Investig"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2354.2008.01004.x","article-title":"Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel\/epidoxorubicin\/cyclophosphamide","volume":"19","author":"Montella","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"15374","DOI":"10.1038\/s41598-019-51982-4","article-title":"Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-019-00356-3","article-title":"Efficacy and safety of supportive care biosimilars among cancer patients: a systematic review and meta-analysis","volume":"33","author":"Yang","year":"2019","journal-title":"BioDrugs"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1007\/s00520-020-05603-w","article-title":"Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s12325-018-0798-6","article-title":"Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia","volume":"35","author":"Cornes","year":"2018","journal-title":"Adv Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/theoncologist.2016-0011","article-title":"A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a phase III, randomized, double-blind trial","volume":"21","author":"Blackwell","year":"2016","journal-title":"Oncologist"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/1042819031000063462","article-title":"Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma","volume":"44","author":"George","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2019.07.95","article-title":"Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial","volume":"7","author":"Xu","year":"2019","journal-title":"Ann Transl Med"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12032-015-0537-7","article-title":"An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy","volume":"32","author":"Zhang","year":"2015","journal-title":"Med Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-015-3418-z","article-title":"Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy","volume":"151","author":"Yuan","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"R29-20250504","first-page":"861","article-title":"Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China","volume":"42","author":"Wen","year":"2020","journal-title":"Chin J Oncol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1007\/s00520-020-05603-w","article-title":"Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis","volume":"28","author":"Li","year":"2020","journal-title":"Support Care Cancer"},{"key":"R31-20250504","first-page":"23","article-title":"A multicenter, randomized, controlled, phase clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer","volume":"38","author":"Xu","year":"2016","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R32-20250504","first-page":"495","article-title":"Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor","volume":"25","author":"Shi","year":"2006","journal-title":"Ai Zheng"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)","volume":"10","author":"Molineux","year":"2004","journal-title":"Curr Pharm Des"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cllc.2015.12.002","article-title":"A randomized multicenter phase III study of single administration of mecapegfilgrastim (HHPG-19K), a pegfilgrastim biosimilar, for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung cancer (NSCLC)","volume":"17","author":"Zhou","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3892\/etm.2014.2160","article-title":"Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia","volume":"9","author":"Wu","year":"2015","journal-title":"Exp Ther Med"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-017-4609-6","article-title":"Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study","volume":"168","author":"Xie","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00520-018-4522-5","article-title":"Real-world safety experience of tevagrastim\/ratiograstim\/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors","volume":"27","author":"Abboud","year":"2019","journal-title":"Support Care Cancer"},{"key":"R38-20250504","first-page":"08","article-title":"Clinical curative effect comparation of polyethylene glycol(peg)of recombinant human granulocyte stimulating factor and recombinant human granulocyte stimulating factor","volume":"11","author":"Dong","year":"2014","journal-title":"Med Innovat China"},{"key":"R39-20250504","first-page":"40","article-title":"Clinical study of PEGylated recombinant human granulocyte stimulating factor prevents neutrophils after chemotherapy","volume":"28","author":"Chi","year":"2018","journal-title":"J Shanxi Med Coll Contin Educ"},{"key":"R40-20250504","first-page":"546","article-title":"The effect of PEG-rhG-CSF on neutropenia caused by chemotherapy after breast cancer surgery","volume":"47","author":"Wu","year":"2018","journal-title":"Chongqing Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.21037\/atm.2019.04.10","article-title":"A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"R42-20250504","first-page":"1231","article-title":"A multicenter, randomized, controlled, phase - clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer","volume":"98","author":"Jiang","year":"2018","journal-title":"Nat Med J China"},{"key":"R43-20250504","first-page":"44","article-title":"Prevention value of PEG-rhG-CSF for cervical cancer with concurrent chemoradiotherapy","volume":"47","author":"Ma","year":"2020","journal-title":"Med J Wuhan Univ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:08:18Z","timestamp":1746338898000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028218"}},"subtitle":["A systematic review and meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":43,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028218","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-07-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}